WAVE Life Sciences's book value per share for the quarter that ended in Sep. 2024 was $0.95.
During the past 3 years, the average Book Value Per Share Growth Rate was -41.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of WAVE Life Sciences was -29.60% per year. The lowest was -41.90% per year. And the median was -31.40% per year.
WAVE Life Sciences's current price is $13.44. Its book value per share for the quarter that ended in Sep. 2024 was $0.95. Hence, today's PB Ratio of WAVE Life Sciences is 14.09.
During the past 11 years, the highest P/B Ratio of WAVE Life Sciences was 30.10. The lowest was 1.40. And the median was 5.93.
WAVE Life Sciences Book Value per Share Historical Data
The historical data trend for WAVE Life Sciences's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WAVE Life Sciences's Book Value per Share
For the Biotechnology subindustry, WAVE Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's PB Ratio falls into.
WAVE Life Sciences Book Value per Share Calculation
WAVE Life Sciences's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
WAVE Life Sciences (NAS:WVE) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
WAVE Life Sciences Book Value per Share Related Terms
Thank you for viewing the detailed overview of WAVE Life Sciences's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WVE has been successfully added to your 